The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia
Abstract
To establish gestational phase adapted cutoffs for the use of the soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio as a diagnostic tool for preeclampsia in the clinical setting, a multicenter case–control study including a total of 1149 patients was performed. We report normal values of sFlt-1, PlGF, and the sFlt-1/PlGF ratio based on the analysis of a total of 877 patients with uneventful pregnancy outcome. A total of 234 patients with preeclampsia and a matched cohort consisting of 468 patients with normal pregnancy outcome were compared, and sFlt-1 and PlGF were measured on an automated platform. Separate cutoffs for the sFlt-1/PlGF ratio were determined for the early (20+0–33+6 weeks) and the late gestational phase (34+0 weeks–delivery). For each of the 2 gestational phases, 2 independent cutoffs framing an equivocal zone were determined: the first cutoff with focus on high sensitivity, and the second focusing on high specificity. Between 20+0 and 33+6 weeks, the cutoffs at ≤33 and ≥85 resulted in a sensitivity/specificity of 95%/94% and 88%/99.5%, respectively. An sFlt-1/PlGF ratio of ≤33 had the lowest likelihood of a negative test (0.05; 95% confidence interval, 0.02–0.13), whereas values ≥85 had the highest likelihood of a positive test (176; 95% confidence interval, 24.88–1245). After 34+0 weeks, the cutoffs at ≤33 and ≥110 yielded a sensitivity/specificity of 89.6%/73.1% and 58.2%/95.5%, respectively. The approach to use multiple cutoffs for the early and late gestational phase enhances the diagnostic accuracy of the sFlt-1/PlGF ratio as a diagnostic tool for preeclampsia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720
(2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.107928 · Cited by 3,270
Steegers, E. A., von Dadelszen, P., Duvekot, J. J., & Pijnenborg, R. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60279-6 · Cited by 2,850
Circulating angiogenic factors and the risk of preeclampsia*
(2004) · Obstetrics & Gynecology · doi:10.1097/00006250-200405000-00028 · Cited by 2,615
Brown, M. A., Lindheimer, M. D., Swiet, M. D., Assche, A. V., & Moutquin, J.-M. (2001) · Hypertension in Pregnancy · doi:10.1081/prg-100104165 · Cited by 1,894
Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
Levine, R. J., Lam, C., Qian, C., Yu, K. F., Maynard, S. E., Sachs, B. P., Sibai, B. M., Epstein, F. H., Romero, R., Thadhani, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055352 · Cited by 1,802
Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
(2006) · New England Journal of Medicine · doi:10.1056/nejmx060063 · Cited by 1,235
Practice bulletin #33: diagnosis and management of preeclampsia and eclampsia
ACOG Committee on Obstetric Practice (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(01)01747-1 · Cited by 1,058
Gynecologists (2009) · Cited by 1,035
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia
Rana, S., Powe, C. E., Salahuddin, S., Verlohren, S., Perschel, F. H., Levine, R. J., Lim, K.-H., Wenger, J. B., Thadhani, R., & Karumanchi, S. A. (2012) · Circulation · doi:10.1161/circulationaha.111.054361 · Cited by 668 · cited 1×
“blood pressure and proteinuria, the sFlt-1/PlGF ratio is able to improve prediction of adverse preeclampsia-related outcomes.(9)”
Background
Cited by
Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia
Zeisler, H., Llurba, E., Chantraine, F., Vatish, M., Staff, A. C., Sennström, M., Olovsson, M., Brennecke, S. P., Stepan, H., Allegranza, D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1414838 · Cited by 1,783
Self-citationStepan, H., Herraiz, I., Schlembach, D., Verlohren, S., Brennecke, S., Chantraine, F., Klein, E., Lapaire, O., Llurba, E., Ramoni, A., et al. (2015) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.14799 · Cited by 264
Self-citationStepan, H., Galindo, A., Hund, M., Schlembach, D., Sillman, J., Surbek, D., & Vatish, M. (2023) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.26032 · Cited by 245
Self-citationHong, J., Crawford, K., Cavanagh, E., da Silva Costa, F., & Kumar, S. (2024) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.27513 · Cited by 21
Metadata
- Authors
- Verlohren, S., Herraiz, I., Lapaire, O., Schlembach, D., Zeisler, H., Calda, P., Sabria, J., Markfeld-Erol, F., Galindo, A., Schoofs, K., Denk, B., & Stepan, H.
- Venue
- Hypertension
- Published
- 2014-02
- Volume
- 63
- Issue
- 2
- Pages
- 346-352
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2170867031
- Cited by
- 372
- References
- 23
- FWCI
- 20.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia. https://app.cochat.ai/papers/10.1161/hypertensionaha.113.01787
- The paper
- Verlohren, S., Herraiz, I., Lapaire, O., Schlembach, D., Zeisler, H., Calda, P., Sabria, J., Markfeld-Erol, F., Galindo, A., Schoofs, K., Denk, B., & Stepan, H. (2014). New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia. Hypertension. https://doi.org/10.1161/hypertensionaha.113.01787
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.